So proud to be associated with the incredible team. Rahul Purwar Gaurav Narula MD Alka Dwivedi Atharva Karulkar you are an inspiration to all the researchers who want to help patients. What you dreamt of is now a reality, ' Dreams do come true'?

Hon'ble President of India officially launches & dedicates NexCAR19 to the Nation.

ICMR congratulates IIT Bombay and Tata Memorial Hospital for launching India’s 1st home-grown gene therapy for cancer! 🇮🇳 Accessible & affordable CAR-T cell therapy offers new hope for all of humanity. A landmark moment in medical science! #MakeInIndia #MedicalBreakthrough

Heartiest Congratulations . So very well done .A proud moment for all .This will have a huge impact on affordable healthcare .The ecosystem has matured and we hope to see more such innovations becoming accessible #MakeInIndia Dr Jitendra Singh (मोदी का परिवार) Ministry of Health DBT-BIRAC

A memorable day where the Hon'ble President dedicated India's first CAR-T therapy to the nation. Frugal innovation, a result of a great collaboration between Tata Memorial Hospital & IIT Bombay with the team led by Rahul Purwar Hasmukh Jain Gaurav Narula MD culminating in ImmunoACT

Grateful & Inspired by your words Hon’ble President of India
dedicating #CARTRx to the nation 🇮🇳
Proud to meet Supreme Commander 🫡
Thankful for our partnership Tata Memorial Hospital IIT Bombay ImmunoACT Rahul Purwar Hasmukh Jain 🙏
Was a long road to get here- my navigator
Yol Bolsun…

We are thrilled and honoured by your esteemed presence Hon President Madam President of India and dedicate CAR-T cell therapy to nation. Hopefully this will help million of patients. Hasmukh Jain Gaurav Narula MD NIH Nirali Shah Laurus Labs Tata Memorial Hospital IIT Bombay

We're honored to announce that Immunoact has been recognized with the prestigious award for Outstanding Achievement in Immunotherapy at Precision Med India 2024. This recognition is a testament to our dedication to advancing healthcare through innovative CAR-T cell therapies

Well researched!🙏 Devina Sengupta.
CAR-T therapy- indigenously developed #MakeInIndia gene therapy puts India on Global map. Exceptional collaboration IIT Bombay Tata Memorial Hospital Hasmukh Jain Jayashree Thorat Gaurav Narula MD ImmunoACT & NCI Center for Cancer Research Alka Dwivedi Atharva Karulkar

Unlocking Clinical Insights: Join Gaurav Narula MD as he dives into real-world case studies, revealing strategies to tackle post CAR-T infusion toxicities.

Date - 7th March 2024, at 04:30 PM
Link for webinar - us06web.zoom.us/j/86578710577?…

Thanks to the entire Apollo Proton Cancer Centre | #WinningOverCancer Cancer Centre, Chennai team for hosting us and an interesting exchange of ideas on how we can leverage #cartcelltherapy together for the greater good of patients in India and beyond
Special thanks to Karan Puri, Dr Jose Easow, Dr. Prasad Eswaran

Pleasure to be hosted by one of the earliest & prominent Bone Marrow Transplant centres in the country at Apollo Cancer Centre, Chennai Centre, Chennai. Special thanks to Dr. T. Raja and the entire team for an excellent engagement and charting a way for the future of #cartcelltherapy in India.

We are glad to have taken a significant step in providing our CAR-T cell therapies affordably and expandably across India, in collaboration with one of the country's earliest & foremost cancer care centres, Cancer Institute (WIA), Chennai

Our Co-Founder & Head of Scientific Affairs, Atharva Karulkar highlighted our CAR-T platform which is now commercially approved for treating certain rare B-cell cancers, to representatives including Dr. V K Paul, Member NITI Ayog, & Bill Gates of the Bill & Melinda Gates Foundation

We've been featured in the Times of India, from our beginnings at IIT Bombay through to our clinical journey heralded by Tata Memorial Hospital and now - as the country's first in gene-modified cell therapies, available nationwide.

timesofindia.indiatimes.com/home/science/w…

NexCAR19 is now available across HospitalsApollo cancer centres in India!

ImmunoACT partners with St John’s Hospital, Bengaluru. A key step in our mission to broaden access to our gene-modified therapies, starting with our revolutionary CAR-T Cell Therapy, NexCAR19, for treating B-cell lymphomas and B-acute lymphoblastic leukaemia in patients 15 years+

We're pleased to announce another milestone in our quest to provide access to our CAR-T cell therapies beginning with #NexCAR19 across India and beyond, through a commercial collaboration with Cytecare Hospitals hospitals, Bengaluru.

health.economictimes.indiatimes.com/news/hospitals…

Excellent article published by NIH/NCI. Can't thank enough National Cancer Institute for their support.